A message from our CEO

Thank you for taking the time to learn about Bexa. We’re working hard to continuously advance the sophistication of Bexa and to establish its role in the early detection of breast cancer through continued use and traditional clinical validation studies. 

Early detection is a critical factor in determining the suffering and death produced by invasive breast cancers. The best means of reducing the impact of breast cancer is an effective, annual early detection examination every year beginning at age 40. Based upon cancer incidence in younger women, African and African American women should start screening at age 35, and Arab women should start no later than age 30.   

Currently, the only widely recommended early detection examination is mammograms.  Mammograms are a very valuable technology and have saved many, many lives over time. Bexa does not aim to be a replacement for mammograms, and we never want to be confused as diminishing or challenging the importance of such a valuable technology. But here we must do a “reality check.” Globally, more than 90% of women will not have mammograms. That’s 1.3 billion women with low early detection rates that cause breast cancers to most often be diagnosed until late stages when treatment is harsh and survival is low. Integration of effective, inexpensive technologies like Bexa is an emergency.

Low participation in current screening programs (for any reason) isn’t a “women’s problem,” it’s every society’s problem, because the impact of late-stage cancers is far broader than just cancer treatment costs. Families are destabilized, income lost, childcare is often unavailable…” everything is affected.” If there’s anything that’s made clear by experience to date, it’s that additional solutions are needed. 

We know that women are needlessly suffering and dying in the absence of innovation, and that an efficient investment in effective early detection of invasive breast cancer that is widely adopted will deliver rich rewards. 

Knowing that current screening options for the most common women’s cancer protect less than 10% of women and resisting the clinical adoption of new early detection options, is not okay. It’s not clinically, financially or morally sound. Women, wives, sisters, daughters and mothers are the foundation of every society; the only thing that is okay is to work every day to find a way to protect women from one of their greatest risks. This is our mission at Sure, Inc., and with Bexa.

Joe Peterson, MD
Chairman & CEO